Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Rinri Therapeutics Ltd.
Headquarters: Sheffield, United Kingdom
Website: https://rinri-therapeutics.com...
Year Founded: 2018
Status: Private
BioCentury | Apr 30, 2024
Management Tracks
New CEOs at Evox and George Medicines
Plus: Stoke hires Thomas Leggett as CFO, and updates from TScan, Rinri, Tevogen and more
BioCentury | Apr 22, 2021
Finance
April 21 Quick Takes: $50M for Sense Biodetection to expand portfolio; plus semaglutide, Porton, Seed Health, Rinri, Mestag, Lyndra
A $50 million series B round led by Koch Disruptive Technologies positions Sense Biodetection Ltd. to launch its Veros COVID-19 molecular test and build out a portfolio of tests for other indications
BioCentury | Feb 2, 2021
Management Tracks
Merck vet Drouet joining CRISPR; plus updates from Cerevance, Rinri, MOMA, Vivoryon, Kadimastem
Gene editing play CRISPR Therapeutics AG (NASDAQ:CRSP) hired Philippe Drouet as chief commercial officer. He was SVP, global oncology marketing & market access at Merck & Co. Inc. (NYSE:MRK),
BioCentury | Dec 21, 2020
Management Tracks
CFO transitions at Translate, Spero, Ziopharm, Precision, CASI, Tessa, Kiniksa and Aquestive; plus updates from 3T, Novavax, Alnylam and more
mRNA company Translate Bio Inc. (NASDAQ:TBIO) announced John Schroer will step down as CFO at year-end. VP and corporate controller Robert Prentiss will serve as principal accounting officer on an
BioCentury | Feb 22, 2020
Product Development
Regenerative medicine for hearing loss makes quiet progress
An analysis of the competitive landscape in regenerative therapies for hearing loss
BioCentury | May 20, 2019
Finance
Boehringer Ingelheim, UCB venture arms seed hearing loss newco Rinri
Disease-modifying data convinced Boehringer Ingelheim Venture Fund to co-lead the seed round for U.K. stem cell hearing loss company Rinri
Items per page:
1 - 6 of 6